Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

Derosa, Giuseppe; D’Angelo, Angela; Salvadeo, Sibilla A T; Ferrari, Ilaria; Gravina, Alessia; Fogari, Elena; Maffioli, Pamela; Cicero, Arrigo F G

doi:10.1016/j.metabol.2008.06.010

Cited by 13 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one of our previous studies we already demonstrated that sibutramine is more effective than diet and physical activity alone in reducing body weight in obese patients with T2DM treated with pioglitazone (28), while we did not observe any differences between the two treatments regarding lipid profile, glycemic control and blood pressure (28). We also demonstrated that sibutramine appears to be a tolerable and efficacious drug when added to pioglitazone for the global management of obese diabetic patients (28,29).…”

Section: Discussionsupporting

confidence: 53%

“…We also demonstrated that sibutramine appears to be a tolerable and efficacious drug when added to pioglitazone for the global management of obese diabetic patients (28,29). Regarding the effects of L-carnitine alone in T2DM, Mingrone et al (30) already reported that L-carnitine constant infusion improves insulin sensitivity in insulin-resistant diabetic patients; a significant effect on whole body insulin-mediated glucose uptake is also observed in normal subjects.…”

Section: Discussionmentioning

confidence: 52%

See 1 more Smart Citation

Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients

et al. 2010

Self Cite

View full text Add to dashboard Cite

Objective To evaluate the effects of one year of treatment with sibutramine plus L-carnitine compared to sibutramine on body weight, glycemic control, and insulin resistance state in type 2 diabetic patients. Methods Two hundred and fifty-four patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA1c) >8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg plus L-carnitine 2 g or sibutramine 10 mg in monotherapy. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, high sensitivity-C reactive protein (Hs-CRP). Results There was a decrease in body weight, BMI, HbA1c, FPI, HOMA-IR, and RBP-4 in both groups, even when the values obtained with sibutramine plus L-carnitine were lower than the values obtained in sibutramine group. There was a faster decrease of FPG, PPG, TC, LDL-C, resistin and Hs-CRP with sibutramine plus L-carnitine even when no differences between the two groups were obtained. Furthermore, only sibutramine plus L-carnitine improved Tg, and visfatin. Conclusion Sibutramine plus L-carnitine gave a faster improvement of lipid profile, insulin resistance parameters, glycemic control, and body weight compared to sibutramine.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 52%

Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…In conjunction with lifestyle and dietary advice, sibutramine can induce weight loss of 5–10% in most patients (19, 20), including those with comorbidities such as controlled hypertension (21) and type 2 diabetes (10, 22). We observed that sibutramine gave a significant 10% improvement of body weight, not observed with placebo; this is in‐line with what has been previously reported by our group (16), and by Finer et al. (10).…”

Section: Resultssupporting

confidence: 93%

“…Sibutramine was safe and well tolerated, and adverse effects were mostly mild or moderate in severity (10). Our group conducted several studies where sibutramine appeared to be a tolerable and efficacious drug when added to pioglitazone for the global management of obese diabetic patients (16, 17).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients

Derosa

Maffioli

Ferrari

et al. 2010

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Long-term effects of weight-reducing drugs in hypertensive patients

Siebenhofer

Horvath

Jeitler

et al. 2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

In patients with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree. In the same trials, orlistat reduced blood pressure and sibutramine increased blood pressure. No trials investigating rimonabant in people with elevated blood pressure could be included. Long-term trials assessing the effect of orlistat, sibutramine and rimonabant on mortality and morbidity are needed.

show abstract

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

Cited by 13 publications

References 29 publications

Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients

Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients

Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients

Long-term effects of weight-reducing drugs in hypertensive patients

Contact Info

Product

Resources

About